ASC Therapeutics Joins U.S. Consortium of Gene Therapy Partners Including the NIH and FDA to Accelerate Treatments for Rare Diseases
Public, private and non-profit organizations have joined forces to create a standardized approach that will reduce up-front costs and lower barriers to developing novel gene therapies for rare and ultra-rare diseases MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies has joined … Read more